



## Vaccination Progress in COVID-19 and HPV

Guest Editor:

### Dr. Wangnan Cao

Department of Social Medicine  
and Health Education, School of  
Public Health, Peking University  
Health Science Center, Beijing  
100191, China

Deadline for manuscript  
submissions:

**closed (30 April 2024)**

### Message from the Guest Editor

Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach for curbing the COVID-19 pandemic. Over a year into the biggest vaccination campaign in history, more than 12.7 billion doses have been administered across 184 countries. The human papillomavirus (HPV) vaccine helps to protect against cancers caused by HPV, including **cervical cancer**, some **mouth and throat cancers**, and some cancers of the anal and genital areas. The current global COVID-19 pandemic threatens to derail the uptake of HPV vaccination in low- and lower-middle income countries, which has a major impact on the World Health Organization cervical cancer elimination strategy, which is dependent on HPV vaccination as well as cervical cancer screening and treatment. This Special Issue welcomes submissions across the broadest interpretation of these issues.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)